Sponsor Pipeline

Merck (MSD) Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
188
Active Trials
120
Recruiting
76
Phase 3
10
Disease Areas
100
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-06-12 NCT07489495
A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell…
Trial sites expanded: 25 -> 34 locations
2026-06-11 NCT07405177
A Study of MK-7240 in Healthy Participants (MK-7240-009)
overall status: "Recruiting" → "Active Not Recruiting"
2026-06-10 NCT07363590
A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004)
Trial sites expanded: 12 -> 15 locations
2026-06-10 NCT07221474
A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in…
Trial sites expanded: 47 -> 51 locations
2026-06-09 NCT07318558
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer…
Trial sites expanded: 77 -> 89 locations
2026-06-09 NCT06345729
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS…
Trial sites expanded: 222 -> 225 locations
2026-06-09 NCT07419295
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer…
Trial sites expanded: 42 -> 50 locations
2026-06-09 NCT06814145
Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)
overall status: "Recruiting" → "Active Not Recruiting"
2026-06-09 NCT07489495
A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell…
Trial sites expanded: 20 -> 25 locations
2026-06-09 NCT06997497
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People…
Trial sites expanded: 192 -> 196 locations
2026-06-09 NCT04924075
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL)…
Enrollment increased: 322 -> 355 participants
2026-06-09 NCT04924075
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL)…
date change Primary completion pushed: 2029-06-04 -> 2029-12-27
2026-06-09 NCT04924075
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL)…
date change Completion pushed: 2029-06-04 -> 2029-12-27
2026-06-09 NCT07405164
Extension Study for Participants in Studies That Include Belzutifan…
Trial sites expanded: 15 -> 20 locations
2026-06-09 NCT07216703
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab…
Trial sites expanded: 115 -> 125 locations
2026-06-09 NCT07190248
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With…
Trial sites expanded: 170 -> 175 locations
2026-06-09 NCT07486960
Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)
Trial sites expanded: 38 -> 41 locations
2026-06-09 NCT04895722
Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments…
Trial arms changed: 5 -> 7
2026-06-06 NCT05017012
A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC)…
Trial completed
2026-06-06 NCT05017012
A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC)…
Enrollment increased: 72 -> 142 participants
Showing 20 of 100 changes detected in the last 30 days.
New Trial Filings, Last 30 Days
First PostedTrialPhaseStatus
2026-06-08 NCT07634471 A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007) Phase 2/3 Not Yet Recruiting
2026-06-05 NCT07630974 A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory… Phase 1/2 Not Yet Recruiting
2026-06-02 NCT07619443 A Clinical Study of MK-7262 and Enlicitide in Healthy Participants (MK-7262-003) Phase 1 Not Yet Recruiting
2026-05-29 NCT07614984 A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a)… Phase 2 Not Yet Recruiting
2026-05-22 NCT07600723 A Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) in… Phase 4 Not Yet Recruiting
2026-05-22 NCT07600749 Clinical Study of MK-4884 in Participants With Advanced or Metastatic Solid Tumors… Phase 1 Not Yet Recruiting
2026-05-22 NCT07600775 A Clinical Trial of MK-8527 and Rifampin in Adult Participants With Latent Tuberculosis… Phase 1 Not Yet Recruiting
2026-05-19 NCT07595263 A Study of Ulonivirine (MK-8507) and Methadone in Healthy Volunteers (MK-8507-019) Phase 1 Not Yet Recruiting
Active Trials by Phase
Phase 4
1
Phase 3
70
Phase 2/3
6
Phase 2
43
Phase 1/2
35
Phase 1
32
Not specified
1
Active Trials — top 25 of 188
NCT IDTitleConditionStatus
Phase 4
NCT07600723 A Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) in… Pulmonary Arterial Hypertension Not Yet Recruiting
Phase 3
NCT06351631 A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017) Thrombocythemia, Essential Recruiting
NCT06136624 Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) Prostate Cancer Metastatic Recruiting
NCT07013487 A Study to Evaluate V181 Dengue Vaccine in Healthy Participants 2 to 17 Years of Age… Healthy Recruiting
NCT06623422 A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in… Carcinoma, Non-Small-Cell Lung Recruiting
NCT06655883 A Study of Suvorexant (MK-4305) for the Treatment of Insomnia Disorder in Participants… Insomnia Recruiting
NCT05947851 A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line… Leukemia, Lymphocytic, Chronic, B-Cell Recruiting
NCT06651281 Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With… Crohn Disease Recruiting
NCT06312137 A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab… Non Small Cell Lung Cancer Recruiting
NCT06077760 A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus… Non-small Cell Lung Cancer Recruiting
NCT06136559 A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib… Chronic Lymphocytic Leukemia Recruiting
NCT06841354 A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination… Triple Negative Breast Neoplasms Recruiting
NCT06925737 A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate… Prostate Cancer Recruiting
NCT06079879 A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in… Essential Thrombocythemia Recruiting
NCT07071623 A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010) Human Immunodeficiency Virus (HIV) Recruiting
NCT07159763 A Study to Evaluate the Safety and Efficacy of CD388 for Prevention of Influenza Influenza Recruiting
NCT06952504 A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab… Endometrial Cancer Recruiting
NCT07431827 MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC… Non-small Cell Lung Cancer Recruiting
NCT07554339 A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell… Non-small Cell Lung Cancer Recruiting
NCT07227402 A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer… Renal Cell Carcinoma Recruiting
NCT03486873 Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who… Solid Tumors Recruiting
NCT06667700 A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019… Coronavirus Disease (COVID-19) Recruiting
NCT06170788 Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab… Non-small Cell Lung Cancer (NSCLC) Recruiting
NCT06312176 A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With… Breast Neoplasms Recruiting
NCT06345729 A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS… Non-small Cell Lung Cancer Recruiting
View all 188 active Merck (MSD) trials with filters →
Disease Areas
Get alerts when Merck (MSD)'s trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free